Biotech Calendar: Key FDA Action Dates
Back by popular demand, I've compiled a calendar of expected U.S. Food and Drug Administration approval decisions.
These can be make-or-break events for drug and biotech companies, so naturally, FDA decisions often move stocks significantly.
The following calendar covers most of the expected drug approval decisions by the FDA through the end of the year. To be included in this FDA calendar, a drug must already be submitted and under review by the agency. For reasons of space, I left out pending FDA approvals for the large pharmaceutical companies.
I put the calendar together using company reports and the BioMedTracker service from Sagient Research -- a handy, subscription-based tool for keeping track of biotech and drug catalysts.Hemispherx Biopharma (HEB)
Drug/indication: Ampligen for chronic fatigue syndrome
FDA decision date: May 25 Hemispherx announced May 26 that the FDA requested a "brief delay" of one to two weeks to take actionf on the Ampligen application. Savient Pharmaceuticals (SVNT)
Drug/indication: Krystexxa for gout
FDA advisory panel date: June 16
FDA decision date: Aug. 1 FDA advisory panel meetings in which outside experts offer recommendations on the approval of drugs are another important stock-moving event. Investors will be keying on the June 16 panel for Krystexxa for indications on how the FDA will ultimately rule on the drug's approval later in the year. BioDelivery Sciences (BDSI)
Drug/indication: Onsolis for breakthrough cancer pain
FDA decision date: June 15 Onsolis is a fast-dissolving film applied to the lining of the mouth that delivers the potent painkiller fentanyl. The FDA sent a complete response letter on Onsolis last August requesting a risk-management plan for the drug. BioDelivery resubmitted Onsolis to the FDA in December. Commercial rights to the drug in North America and Europe were licensed to Meda AB, a specialty pharmaceutical firm.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV